Press Releases - G1 Therapeutics, Inc.

Press Releases

Date	Title
5/3/23	G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
5/1/23	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/26/23	G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
4/11/23	G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
3/1/23	G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
2/28/23	G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
2/22/23	G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023
2/13/23	G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)
2/1/23	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/11/23	G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference